Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 7/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | RARA | P10276 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13452757 | 1.00 | RARB (0.51) | RARBMAPTMEN1ALDH1A1RARA | |
| SCHEMBL31404687 | 0.93 | RARB (0.46) | RARBMAPTMEN1ALDH1A1RARA | |
| SCHEMBL31404689 | 0.90 | RARB (0.44) | RARBMAPTMEN1ALDH1A1RARA | |
| SCHEMBL12199942 | 0.88 | TAOK1 (0.48) | MAPTMEN1KMT2ASMN1; SMN2NCEH1 | |
| SCHEMBL15292221 | 0.87 | RARB (0.52) | RARBMAPTMEN1ALDH1A1RARA | |
| SCHEMBL881059 | 0.87 | RARB (0.53) | RARBMAPTKMT2ASMN1; SMN2CNR2 | |
| SCHEMBL9150991 | 0.87 | THRB (0.40) | RARBMAPTSMN1; SMN2THRBNCEH1 | |
| SCHEMBL881060 | 0.86 | RARB (0.55) | RARBMAPTKMT2ASMN1; SMN2CNR2 | |
| SCHEMBL9155670 | 0.86 | BCHE (0.42) | RARBMAPTMEN1ALDH1A1RARA | |
| SCHEMBL12199949 | 0.84 | TAOK1 (0.46) | MAPTMEN1KMT2ASMN1; SMN2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8974694-B2 | Liquid-crystal composition | JNC CORPORATION (JP) | 2015-03-10 | — | — | US | disclosed |
| US-8580144-B2 | Blue phase liquid crystal nanocomposites and devices containing the same | KENT STATE UNIVERSITY (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130188107-A1 | LIQUID-CRYSTAL COMPOSITION | JNC PETROCHEMICAL CORPORATION (JP) | 2013-07-25 | — | — | US | disclosed |
| US-8409673-B2 | Chlorobenzene derivative, optically isotropic liquid crystal medium, and optical device | JNC CORPORATION (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20120262662-A1 | BLUE PHASE LIQUID CRYSTAL NANOCOMPOSITES AND DEVICES CONTAINING THE SAME | KENT STATE UNIVERSITY (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120099039-A1 | CHLOROBENZENE DERIVATIVE, OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM, AND OPTICAL DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-04-26 | — | — | US | disclosed |
| EP-2433923-A1 | CHLOROBENZENE DERIVATIVE, OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM, AND OPTICAL ELEMENT | JNC Corporation (JP) | 2012-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120099039-A1 | CHLOROBENZENE DERIVATIVE, OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM, AND OPTICAL DEVICE | CRYAB, CYBA, CCNB1 | RARB 153/4885MAPT 126/4885MEN1 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.